Proposed Data Collections Submitted for Public Comment and Recommendations

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[INFO-97-04]

Proposed Data Collections Submitted for Public Comment and

Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995 for opportunity for public comment on

proposed data collection projects, the Centers for Disease Control and

Prevention (CDC) will publish periodic summaries of proposed projects.

To request more information on the proposed projects or to obtain a

copy of the data collection plans and instruments, call the CDC Reports

Clearance Officer on (404) 639-7090.

Comments are invited on: (a) Whether the proposed collection of

information is necessary for the proper performance

[[Page 7460]]

of the functions of the agency, including whether the information shall

have practical utility; (b) the accuracy of the agency's estimate of

the burden of the proposed collection of information; (c) ways to

enhance the quality, utility, and clarity of the information to be

collected; and (d) ways to minimize the burden of the collection of

information on respondents, including through the use of automated

collection techniques for other forms of information technology. Send

comments to Wilma Johnson, CDC Reports Clearance Officer, 1600 Clifton

Road, MS-D24, Atlanta, GA 30333. Written comments should be received

within 60 days of this notice.

Proposed Projects

1. The Tri-State Mining District: Lead Exposure and Immunotoxic

Effects Study--New--The proposed study evaluates associations between

immune system dysfunction/damage and exposure to lead among children in

the Tri-State Mining District. This district encompasses several

contaminated areas including three Superfund sites: The Oronogo-Duenweg

Mining Belt site in Jasper County, Missouri; the Cherokee County Site

in Kansas; and the Tar Creek, Ottawa County Site in Oklahoma.

The proposed study consists of two repeated in-person interviews

and biological testing for blood lead and immune function among

participants of the ongoing lead screening programs in the Tri-State

Mining district. Approximately 50 children identified as having blood

lead <10 micrograms per decilitre and 50 children with blood lead

levels <5 micrograms per decilitre will constitute the study and

comparison groups respectively. Blood specimens will be obtained to

measure lead, complete blood count, EP, ZPP, antibody titers, and the

CDC/ATSDR recommended immune panel. A second blood drawn a month later

will examine intra-personal immune tests stability and will help

evaluate the relationship between immune results and recent illness.

Parents will be interviewed using a children's health questionnaire

that solicits information on demographics, the medical history of each

child and the occurrences of recent illness. Statistical analyses will

compare health outcome measures (symptoms, illness, change in immune

parameters) to blood lead levels. Other than their time, there will be

no cost to the respondents. The length of clearance requested is 3

years.

----------------------------------------------------------------------------------------------------------------

Average

Number of Number of burden/ Total

Respondents respondents reponses/ response burden (in

respondent (in hrs) hrs.)

----------------------------------------------------------------------------------------------------------------

Child Health Questionnaire.................................. 100 2 0.5 100

---------------------------------------------------

Total................................................... ........... ........... ........... 100

----------------------------------------------------------------------------------------------------------------

Dated: February 12, 1997.

Wilma G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers

for Disease Control and Prevention (CDC).

[FR Doc. 97-4006 Filed 2-18-97; 8:45 am]

BILLING CODE 4163-18-P